Dupilumab Is Safe and Efficacious for Treatment of Eosinophilic Esophagitis and Atopic Dermatitis in Pediatric Liver Transplant Recipients: A Case Series
- 25 June 2026
- journal article
- case report
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (7) , e70382
Abstract
Background: Transplant‐acquired atopy and allergic disorders, including atopic dermatitis and eosinophilic gastrointestinal disorders, are known complications of organ transplantation. They have been noted to be more prevalent following liver transplantation than other solid organ transplantations. The pathophysiology is unknown; however, tacrolimus immunosuppression has been hypothesized to play a role via T helper 2 cell predominance, leading to increased interleukin‐4 and interleukin‐13 expression. Dupilumab, a monoclonal antibody that downregulates interleukin‐4, interleukin‐13, and the T helper 2 cell pathway, is effective for atopic dermatitis and eosinophilic esophagitis, though there is a paucity of data regarding its use and safety in pediatric liver transplant recipients. Methods and Results: We report a series of cases of pediatric liver transplant recipients from a single center who developed severe atopic dermatitis or eosinophilic esophagitis that was refractory to routine treatments and immunosuppression changes. These atopic conditions also severely affected their quality of life. After initiation of dupilumab, the patients had improvement in both their atopic conditions and quality of life. Patients who did not have evidence of graft dysfunction or rejection prior to initiation of dupilumab maintained normal biochemical graft function. Patients who had rejection prior to starting dupilumab did not develop acute worsening of their graft function or rejection. Conclusions: In this case series, dupilumab was seen to be effective for pediatric liver transplant recipients who developed atopic dermatitis or eosinophilic esophagitis that was refractory to routine treatment and immunosuppression changes. While receiving dupilumab, these patients did not develop worsening graft function or rejection.Keywords
This publication has 10 references indexed in Scilit:
- Corneal Transplant Rejection and Alopecia Areata Universalis in a Patient With Severe Atopic Dermatitis on DupilumabActas Dermo-Sifiliograficas, 2023
- Dupilumab for the Treatment of Severe Atopic Dermatitis in an Immunosuppressed Transplant PatientDermatitis®, 2023
- Use of dupilumab for atopic dermatitis in young transplant patients—A case series of 3 patientsPediatric Dermatology, 2023
- 33863 Successful use of dupilumab for treatment of atopic dermatitis in a liver transplant patientJournal of the American Academy of Dermatology, 2022
- Dupilumab for the treatment of atopic dermatitis in transplant patients: Two case reports and literature reviewDermatologic Therapy, 2022
- De Novo Food Allergy in Pediatric Recipients of Liver TransplantJournal of Pediatric Gastroenterology and Nutrition, 2021
- Effectiveness and safety of dupilumab for atopic dermatitis in a liver transplant recipient: a case reportJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2020
- De Novo Allergy and Immune-Mediated Disorders Following Solid-Organ Transplantation—Prevalence, Natural History, and Risk FactorsThe Journal of Pediatrics, 2018
- The differential expression of IL-4 and IL-13 and its impact on type-2 immunityCytokine, 2015
- Acquired atopic disease after liver transplantation in children; similarities to and differences from adultsEuropean Journal of Gastroenterology & Hepatology, 2014